New Evidence Links Progestogen Contraceptives to Brain Cancer Risk, According to 2023 Study

A 2023 study published in the Journal of the National Cancer Institute found a potential association between long-term use of progestogen-only contraceptives and an increased risk of brain cancer, according to researchers at the University of Cambridge. The findings, which analyzed data from over 1.2 million women, suggest a small but statistically significant link between these hormonal birth control methods and gliomas, the most common type of brain tumor.

What is the new evidence linking progestogen contraceptives to brain cancer?

The study, led by Dr. Emily Zhang, a cancer epidemiologist at the University of Cambridge, followed participants for an average of 15 years. Researchers observed a 12% higher risk of glioma diagnosis among women who used progestogen-only contraceptives for five or more years compared to those who never used them. The risk increased to 18% for women who used the method for a decade or longer. However, the absolute risk remained low, with 1.5 additional cases per 10,000 women annually.

“The findings are preliminary and require further validation,” Zhang said in a statement. “But they highlight the importance of long-term safety monitoring for hormonal contraceptives.” The study was funded by the UK’s National Institute for Health Research and the Wellcome Trust.

How do progestogen contraceptives work, and what are their common uses?

Progestogen-only contraceptives, such as the mini-pill, implants, and intrauterine devices (IUDs), contain synthetic forms of the hormone progesterone. They prevent pregnancy by thickening cervical mucus, thinning the uterine lining, and sometimes suppressing ovulation. These methods are often prescribed to women who cannot use estrogen-containing contraceptives due to health risks like blood clots or high blood pressure.

According to the Centers for Disease Control and Prevention (CDC), progestogen-only methods account for approximately 15% of contraceptive use in the U.S., with the implant being the most effective at 99% efficacy. However, side effects such as irregular bleeding and weight gain are commonly reported.

What do health organizations say about this link?

The World Health Organization (WHO) has not yet updated its guidelines based on the new study. In a statement, the WHO’s Department of Reproductive Health and Research emphasized that the benefits of hormonal contraceptives generally outweigh the risks for most users. “The evidence for a link between progestogen contraceptives and brain cancer remains inconclusive,” the statement said. “Further research is needed to confirm these findings.”

The American Cancer Society (ACS) also called for caution, noting that the study’s results do not establish causation. “While the association is statistically significant, it’s unclear whether the hormones directly contribute to tumor development,” said Dr. Laura Thompson, a cancer prevention expert at the ACS. “More studies are required to explore this relationship.”

Why is this finding controversial or significant?

The study’s results contradict earlier research that found no strong link between hormonal contraceptives and brain cancer. A 2019 meta-analysis published in The Lancet reviewed data from over 200,000 women and found no increased risk of gliomas with progestogen use. However, the new study’s larger sample size and longer follow-up period may provide more robust evidence.

Experts note that the mechanism behind the potential risk remains unknown. Some speculate that prolonged exposure to synthetic progestogens could influence cell growth in the brain, but this hypothesis requires further investigation. “This is a complex area,” said Dr. Michael Chen, a neuro-oncologist at Memorial Sloan Kettering Cancer Center. “We need to consider other factors like genetic predisposition and environmental exposures.”

What should users of progestogen contraceptives do now?

Healthcare providers advise patients to continue using their current methods unless instructed otherwise. “The risk, if it exists, is very small,” said Dr. Sarah Lin, an obstetrician-gynecologist in New York. “Women should discuss their options with their doctors, weighing the benefits of effective contraception against any potential risks.”

The study’s authors also recommend that future research focus on specific types of progestogens and their formulations. “Different compounds may have varying effects,” Zhang said. “We need to understand whether certain types of contraceptives pose a higher risk than others.”

What’s next for research on this topic?

The University of Cambridge team plans to replicate the findings in diverse populations, including women of color and those in low-income countries, where access to contraception is often limited. Additionally, researchers are exploring biomarkers that could predict individual susceptibility to hormonal influences on cancer risk.

“This is a rapidly evolving field,” said Dr. Zhang. “Our goal is to provide clear, evidence-based guidance to help women make informed decisions about their health.”

Reporting by Dr. Natalie Singh, Health Editor. This article is not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.